Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 2
1994 2
1996 2
1997 1
1999 1
2003 1
2012 1
2013 2
2014 1
2016 2
2017 2
2018 2
2019 2
2021 6
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study investigators. Cree BAC, et al. Among authors: drappa j. Lancet. 2019 Oct 12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5. Lancet. 2019. PMID: 31495497 Clinical Trial.
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial.
Rensel M, Zabeti A, Mealy MA, Cimbora D, She D, Drappa J, Katz E. Rensel M, et al. Among authors: drappa j. Mult Scler. 2022 May;28(6):925-932. doi: 10.1177/13524585211047223. Epub 2021 Oct 1. Mult Scler. 2022. PMID: 34595983 Free PMC article. Clinical Trial.
Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus.
Karnell JL, Wu Y, Mittereder N, Smith MA, Gunsior M, Yan L, Casey KA, Henault J, Riggs JM, Nicholson SM, Sanjuan MA, Vousden KA, Werth VP, Drappa J, Illei GG, Rees WA, Ratchford JN; VIB7734 Trial Investigators. Karnell JL, et al. Among authors: drappa j. Sci Transl Med. 2021 May 26;13(595):eabf8442. doi: 10.1126/scitranslmed.abf8442. Sci Transl Med. 2021. PMID: 34039741 Clinical Trial.
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.
Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Green AJ, Aktas O, Hartung HP, Lublin FD, Williams IM, Drappa J, She D, Cimbora D, Rees W, Smith M, Ratchford JN, Katz E, Cree BAC; N-MOmentum Study Investigators. Marignier R, et al. Among authors: drappa j. Neurol Neuroimmunol Neuroinflamm. 2021 Mar 26;8(3):e978. doi: 10.1212/NXI.0000000000000978. Print 2021 May. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 33771837 Free PMC article. Clinical Trial.
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
Marignier R, Pittock SJ, Paul F, Kim HJ, Bennett JL, Weinshenker BG, Wingerchuk DM, Green AJ, Fujihara K, Cutter G, Aktas O, Hartung HP, Drappa J, Ratchford JN, She D, Smith M, Rees W, Cimbora D, Katz E, Cree BAC; N-MOmentum study investigators. Marignier R, et al. Among authors: drappa j. Mult Scler Relat Disord. 2022 Jan;57:103356. doi: 10.1016/j.msard.2021.103356. Epub 2021 Nov 1. Mult Scler Relat Disord. 2022. PMID: 35158465 Free article. Clinical Trial.
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
Cree BA, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Williams IM, Drappa J, She D, Cimbora D, Rees W, Ratchford JN, Katz E. Cree BA, et al. Among authors: drappa j. Mult Scler. 2021 Nov;27(13):2052-2061. doi: 10.1177/1352458521988926. Epub 2021 Feb 4. Mult Scler. 2021. PMID: 33538237 Free PMC article. Clinical Trial.
A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity.
Karnell JL, Albulescu M, Drabic S, Wang L, Moate R, Baca M, Oganesyan V, Gunsior M, Thisted T, Yan L, Li J, Xiong X, Eck SC, de Los Reyes M, Yusuf I, Streicher K, Müller-Ladner U, Howe D, Ettinger R, Herbst R, Drappa J. Karnell JL, et al. Among authors: drappa j. Sci Transl Med. 2019 Apr 24;11(489):eaar6584. doi: 10.1126/scitranslmed.aar6584. Sci Transl Med. 2019. PMID: 31019027
27 results